Company: ARTL
Filing Date: 2025-09-30
Form Type: 424B5
Source: 0001640334-25-001749
Chunk: 23

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-09-30
Form: 424B5
Chunk 23
---
 current liabilities                                                                                                   |     | $                    |   5,712 |   |     | $                       | - |
| Stockholders’ equity                                                                                                        |     |                      |         |   |     |                         |   |
| Preferred Stock, par value $0.001, 69,445 shares authorized, 0 shares issued and outstanding as of June 30, 2025            |     |                      |       - |   |     |                         | - |
| Common Stock, par value $0.001, 500,000,000 shares authorized and 704,425 shares issued and outstanding as of June 30, 2025 |     |                      |       1 |   |     |                         |   |
| Additional paid in capital                                                                                                  |     |                      |  54,617 |   |     |                         |   |
| Accumulated deficit                                                                                                         |     |                      | (55,729 | ) |     |                         |   |
| Accumulated other comprehensive loss                                                                                        |     |                      |    (295 | ) |     |                         |   |
| Total stockholders’ (deficit) equity                                                                                        |     | $                    |  (1,406 | ) |     | $                       | - |

The above discussion and table is based on 704,425 shares of our common stock outstanding as of June 30, 2025 (giving effect to the one-for-six reverse stock split of our common stock effected on June 13, 2025), and excludes as of that date:

·227,842 shares of our common stock issuable upon the exercise of options or restricted stock awards granted under our 2018 Equity Incentive Plan (the “2018 Plan”), with a weighted-average exercise price of $11.03 per share;

·23,315 shares of our common stock issuable upon the exercise of warrants, with a weighted-average exercise price of $67.50 per share issued prior to June 30, 2025;

·123,255 shares of common stock issuable upon the voluntary conversion of convertible notes issued in our May 2025 private placement;

·246,511 shares of common stock issuable upon the automatic conversion of convertible notes issued in our May 2025 private placement to warrants to purchase common stock, with an exercise price of $6.24 per share;

·55,300 shares of our common stock issuable upon the exercise of pre-funded warrants issued in our June 2025 private placement, with an